



ELN FRONTIERS MEETING

CONTINUING THE CML REVOLUTION: EXPANDING OPTIONS IN TARGETED THERAPY

18 – 20 SEPTEMBER 2009
BARCELONA, SPAIN

Chairs:
Francisco Cervantes
Michele Baccarani
Rüdiger Hehlmann



WELCOME

Dear Colleague,

We are pleased to invite you to the ELN Frontiers Meeting 2009 entitled: *Continuing the CML Revolution: Expanding Horizons in Targeted Therapy*.

The European LeukemiaNet (ELN), a network of excellence integrating the leading European groups in leukemia research and management, is dedicated to increasing expertise and spreading excellence in chronic myeloid leukemia (CML) research and patient management. In 2006 the ELN provided expert recommendations on CML treatment and management. These were embraced by physicians across Europe and all over the world, and served to standardize treatment paradigms and response assessment. However, as data from CML studies mature, revision and updates become necessary. In 2009, the ELN will put forth revised recommendations on the management of CML. The European Treatment and Outcome Study (EUTOS) was created to disseminate new research findings and best practices in CML in order to improve treatment outcomes across Europe. EUTOS increases understanding of CML incidence and management, expands access to cutting-edge clinical support programs and educates European clinicians with regards to the latest disease management tools and techniques.

Development of targeted therapies has been remarkably successful in treating CML by directly addressing the molecular root of the disease. However, the ultimate goal is to cure CML entirely. How far have we come towards this lofty goal?

This question will be reflected in the program of the ELN Frontiers Meeting 2009. Other complex issues will be debated, updates provided and questions raised:

- What can we learn from the most recent trial data on TKI therapy for CML?
- How can we improve the standard of care in CML?
- What changes have been made in the most recent version of the ELN recommendations for the treatment of CML?
- What are the clinical implications of the predictive factors used in making therapeutic decisions?
- What is known regarding the treatment of myeloproliferative disorders other than CML?
- How can we further improve survival of CML in Europe?
- What advances have been achieved in the biology and treatment of chronic myeloproliferative disorders other than CML?

The answers to these questions will form the landscape of future treatment of CML and help participants to improve the standard of care. Our programme is a blend of presentations, debates and clinical case studies, designed to push forward our understanding of CML in order to continue the CML revolution by transforming lives and extending survival of CML patients.

Yours sincerely,

F. Cervantes, M. Baccarani and R. Hehlmann

AGENDA

DAY 1 – SATURDAY, 19 SEPTEMBER 2009

08:30 – 08:40

Welcome & introduction

Session 1

Focus on first-line therapy

08:40 – 08:50

The IRIS trial: A clinical perspective on the 7-year update

08:50 – 09:00

Can we improve response? The French SPIRIT study

09:00 – 09:10

Survival - Can we do better than IRIS? The German CML-Study IV

09:10 – 09:20

The Hammersmith study: How does it compare?

09:20 – 09:30

Second generation TKIs as first line therapy

09:30 – 09:45

Imatinib in clinical practice

09:45 – 10:00

Management of special CML populations: Pregnant, paediatric and elderly patients

10:00 – 10:20

Questions and answers

10:20 – 10:50

Break

AGENDA

Session 2 Improving the standard of care

- 10:50 – 11:05** EUTOS for CML: Making progress in a successful collaboration
- 11:05 – 11:20** EUTOS CML registries: Gathering, tracking and analysing data to improve future outcomes
- 11:20 – 11:40** EUTOS: Producing quality, controlled outcome in monitoring molecular response and therapeutic blood levels
- 11:40 – 12:00** Molecular response is a necessary addition to CML monitoring – a debate
- 12:00 – 12:20** Mutational analysis alone is sufficient to choose second-line therapy – a debate
- 12:20 – 12:40** Blood level testing is a necessary tool for optimizing CML management – a debate
- 12:40 – 13:00** Questions and Answers
- 13:00 – 14:00** Lunch

Session 3 Monitoring and evaluating response

- 14:00 – 14:15** The ELN recommendations: New data supporting an update
- 14:15 – 14:35** ELN recommendations for the management of CML: The new, revised version
- 14:35 – 14:45** Response criteria for second-generation TKIs
- 14:45 – 15:00** Interpreting the new recommendations: Case in point
- 15:00 – 15:10** The challenges of using the ELN recommendations: A practical perspective
- 15:10 – 15:30** Questions and Answers
- 15:30 – 16:00** Break

Session 4 Clinical implications of predictive factors

- 16:00 – 16:15** The importance of achieving complete cytogenetic response
- 16:15 – 16:30** The value of complete molecular response
- 16:30 – 16:45** Emergence of new mutations under second-generation TKI therapy
- 16:45 – 17:00** The importance of an anti-proliferative index in CML therapy
- 17:00 – 17:10** Dose escalation in a patient not responding to standard dose imatinib
- 17:10 – 17:30** Questions and Answers
- 17:30 – 17:40** Closing Remarks - Day 1

AGENDA

DAY 2 – SUNDAY, 20 SEPTEMBER 2009

Session 5 Philadelphia chromosome negative chronic myeloproliferative disorders

- 08:30 – 08:40** Welcome and Introduction
- 08:40 – 08:55** The molecular biology of classical myeloproliferative disorders
- 08:55 – 09:10** Atypical myeloproliferative disorders: Cytogenetics and molecular biology
- 09:10 – 09:25** Results of JAK2 inhibitor trials
- 09:25 – 09:40** Treatment of eosinophilic leukemias
- 09:40 – 09:55** Systemic mastocytosis: Biology and treatment
- 09:55 – 10:15** Questions and Answers
- 10:15 – 10:45** Break

Session 6 How can we improve clinical outcomes of CML patients?

- 10:45 – 11:00** Resistant and intolerant patients in chronic phase
- 11:00 – 11:15** Treatment of CML in advanced phases
- 11:15 – 11:35** Second-generation TKIs are the preferred treatment for the majority of patients regardless of suitability for transplantation – a debate
- 11:35 – 11:50** Novel agents in the treatment of CML
- 11:50 – 12:05** Vaccines in CML
- 12:05 – 12:20** Eradicating the CML stem cell
- 12:20 – 12:35** Are we approaching a cure?
- 12:35 – 12:55** Questions and Answers
- 12:55 – 13:00** Closing remarks - Day 2
- 13:00 – 14:30** Lunch

FACULTY

Jane F. Apperley, MD, FRCP, FRCPath

Imperial College London
London, United Kingdom

Michele Baccarani, MD

University of Bologna
Bologna, Italy

Monica Bocchia, MD

Siena University
Siena, Italy

Francisco Cervantes, MD

Hospital Clinic Barcelona
Barcelona, Spain

Richard Clark, MD

Royal Liverpool University Hospital
Liverpool, United Kingdom

Nick Cross, MD, PhD

University of Southampton
Salisbury, United Kingdom

Justus Duyster, MD

Technical University of Munich
Munich, Germany

Luis Escribano, MD, PhD

Hospital de Toledo
Toledo, Spain

Francis J. Giles, MB, MD, FRCPI, FRCPath

University of Texas
San Antonio, TX, USA

John M. Goldman, DM, FRCPath

Hammersmith Hospital
London, United Kingdom

François Guilhot, MD

CHU de Poitiers
Poitiers, France

Joerg Hasford, MD

University of Munich
Munich, Germany

Rüdiger Hehlmann, MD

University of Heidelberg
Mannheim, Germany

Andrzej Hellmann, MD, PhD

Medical University of Gdansk
Gdansk, Poland

Andreas Hochhaus, MD

University of Heidelberg
Mannheim, Germany

Timothy P. Hughes, MD, MBBS

Institute of Medical and Veterinary Science
Adelaide, Australia

Robert Kralovics, PhD

Center for Molecular Medicine
Austrian Academy of Sciences
Vienna, Austria

Richard Larson, MD

University of Chicago
Chicago, IL, USA

Philipp Le Coutre, MD

Universitätsklinikum Charité
Berlin, Germany

François-Xavier Mahon, MD, PhD

CHU Pellegrin
Bordeaux, France

David Marin, MD

Hammersmith Hospitals Trust
Imperial College London
London, United Kingdom

Giovanni Martinelli, MD

University of Bologna
Bologna, Italy

Jirí Mayer, MD, PhD

University Hospital Brno and
Medical Faculty MU
Brno, Czech Republic

Martin C. Müller, MD

University of Heidelberg
Mannheim, Germany

Franck E. Nicolini, MD, PhD

Hospital Edouard Herriot
Lyon, France

Stephen G. O'Brien, MD, PhD

University of Newcastle
Newcastle, United Kingdom

Eduardo Olavarria, MD, PhD

Hospital de Navarra
Pamplona, Spain

Oliver G. Ottmann, MD

University of Frankfurt
Frankfurt, Germany

Fabrizio Pane, MD

University of Naples
Naples, Italy

Kimmo Porkka, MD, PhD

Helsinki University Central Hospital
Helsinki, Finland

Delphine Réa, MD, PhD

Service des Maladies du Sang
Hôpital Saint Louis
Paris, France

Andreas Reiter, MD

University of Heidelberg
Mannheim, Germany

Gianantonio Rosti, MD

University of Bologna
Bologna, Italy

Philippe Rousselot, MD

Hospital André Mignot
Le Chesnay, France

Giuseppe Saglio, MD

University of Turin
Turin, Italy

Susanne Saussele, MD

European LeukemiaNet
Mannheim, Germany

Richard T. Silver, MD

Weill Medical College of Cornell University
New York, NY, USA

Bengt Simonsson, MD, PhD

University Hospital
Uppsala, Sweden

Simona Soverini, PhD

University of Bologna
Bologna, Italy

Juan Luís Steegmann, MD, PhD

Hospital Universitario de la Princesa
Madrid, Spain

Ayalew Tefferi, MD

Mayo Clinic College of Medicine
Rochester, MN, USA

Anna G. Turkina, MD

Haematological Research Centre
Russian Academy of Medical Sciences
Moscow, Russia

CME STATEMENTS

This programme for continued medical education focuses on optimising the use of molecularly targeted therapies in hematology/oncology, specifically in chronic myeloid leukemia (CML).

Target audience:

The programme is designed for hematologists, oncologists, and other health care professionals who manage and treat patients with Philadelphia chromosome positive (Ph+) hematological malignancies, specifically CML.

Programme goals:

This programme focuses on optimising the use of molecularly targeted therapies in hematology/ oncology, specifically in CML and will update and inform participants on:

- clinical evidence regarding first-line therapy for CML
- public/private partnerships for improving outcomes and the standard of care for CML in Europe
- the new, revised European LeukemiaNet recommendations for the management of CML
- the clinical implications of predictive factors in CML treatment
- current data regarding Philadelphia chromosome negative myeloproliferative disorders (Ph-negative MPDs)
- how to best improve the clinical outcome of CML patients

Educational objectives:

1. Discuss the most recent data from CML treatment optimization trials and assist in interpreting this data to benefit clinical practice.
2. Discuss the role of the European Treatment and Outcome Study (EUTOS) for CML in advancing knowledge and performance.
3. Recognize and interpret the new ELN recommendations for the management of CML so that cutting edge treatment of CML is maintained.
4. Discuss the importance and clinical implications of molecular outcomes and other predictive factors in CML.
5. Describe the mechanisms of resistance to TKIs and select appropriate treatment options in case of resistance.
6. Explain the molecular biology and treatment options for Ph-negative MPDs.

Accreditation statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Veritas Institute for Medical Education Inc. and SAN GmbH (Science Agency & Network). Veritas Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation of credit statement

Veritas Institute designates this educational activity for a maximum of 10.75 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ is generally accepted as equivalent to EACCME credit in Europe, through a reciprocity agreement between the American Medical Association and the European Union of Medical Specialists (UMES).

Financial and off-label/investigational uses of drugs

The relevant financial relationships of those persons in a position to control the content of this CME activity will be disclosed prior to the start of the educational activity. Participants are advised that this CME activity will contain references to unlabeled/unapproved/investigational uses of drugs that treat CML.

Special needs

On-site staff will be glad to assist you with any special needs, please contact Barbara Moor, +41 62 749 00 80, barbara.moor@sannet.ch.

MEETING VENUE / SCIENTIFIC SECRETARY

Meeting venue

CCIB – Centre Convencions Internacional Barcelona
Rambla Prim 1-17
08019 Barcelona, Spain

Phone: +34 93 230 10 00
Fax: +34 93 230 10 01
www.ccib.es

Scientific secretary

Dr. Susanne Saussele
Scientific Network Manager
European LeukemiaNet
III. Medizinische Klinik
Universitätsmedizin Mannheim
Pettenkofer Strasse 22
68169 Mannheim, Germany

Phone: +49 621 383 6962
Fax: +49 621 383 6969
Email: Susanne.Saussele@umm.de